tetano
Editor, Senior Moderator
Cell Physiol Biochem. 2018 Mar 28;46(2):633-643. doi: 10.1159/000488631. [Epub ahead of print]
[h=1]The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.[/h] Wu XX[SUP]1[/SUP], Deng XL[SUP]2[/SUP], Yu DS[SUP]1[/SUP], Yao W[SUP]3[/SUP], Ou HL[SUP]1[/SUP], Weng TH[SUP]1[/SUP], Hu CY[SUP]1[/SUP], Hu FY[SUP]2[/SUP], Wu NP[SUP]1[/SUP], Yao H[SUP]1[/SUP], Zhang FC[SUP]2[/SUP], Li LJ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND/AIMS:[/h] Since the first case of novel H7N9 infection was reported, China has experienced five epidemics of H7N9. During the fifth wave, a highly pathogenic H7N9 strain emerged. In order to assess whether the H7N9 vaccine based on A/Zhejiang/DTID-ZJU01/2013(H7N9) was effective in protecting against highly pathogenic H7N9, we conducted this study.
[h=4]METHODS:[/h] Groups of mice were immunized twice by intraperitoneal injection with 500 ?l of either split vaccine alone or MF59-adjuvanted vaccine. Serum was collected 2 weeks after the second vaccine booster. The hemagglutinin inhibition test was conducted on vaccine seed and highly pathogenic H7N9 to evaluate the neutralization of highly pathogenic H7N9. We also immunized mice and challenged them with highly pathogenic H7N9. Mice were observed for illness, weight loss, and death at 1 week and 2 weeks post-infection. Then, the mice were sacrificed and lungs were removed. Antibody responses were assessed and pathological changes in the lung tissue were evaluated.
[h=4]RESULTS:[/h] The ability of serum to neutralize highly pathogenic H7N9 was reduced. In mice, highly pathogenic H7N9 was more virulent than A/Zhejiang/DTID-ZJU01/2013(H7N9). After challenge with highly pathogenic H7N9, all mice died while mice challenged with A/Zhejiang/DTID-ZJU01/2013(H7N9) all recovered. The A/ZJU01/PR8/2013 split H7N9 avian influenza vaccine was able to protect against infection with highly pathogenic H7N9 in mice, with or without MF59. Moreover, H7N9 vaccine adjuvanted with MF59 produced high antibody levels, which lead to better protection.
[h=4]CONCLUSIONS:[/h] The A/ZJU01/PR8/2013 split H7N9 avian influenza vaccine based on A/Zhejiang/DTID-ZJU01/2013(H7N9) is effective in protecting against highly pathogenic H7N9. H7N9 vaccine adjuvanted with MF59 offers better protection against infection with highly pathogenic H7N9. In order to make the H7N9 vaccine applicable to humans, further clinical trials are required to evaluate MF59 adjuvanted vaccine. Meanwhile, the vaccine strain should be updated based on the highly pathogenic H7N9 gene sequence.
? 2018 The Author(s). Published by S. Karger AG, Basel.
[h=4]KEYWORDS:[/h] Highly pathogenic H7N9; MF59 adjuvant; Protective immune responses; Split H7N9 vaccine
PMID: 29617693 DOI: 10.1159/000488631
Free full text
[h=1]The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.[/h] Wu XX[SUP]1[/SUP], Deng XL[SUP]2[/SUP], Yu DS[SUP]1[/SUP], Yao W[SUP]3[/SUP], Ou HL[SUP]1[/SUP], Weng TH[SUP]1[/SUP], Hu CY[SUP]1[/SUP], Hu FY[SUP]2[/SUP], Wu NP[SUP]1[/SUP], Yao H[SUP]1[/SUP], Zhang FC[SUP]2[/SUP], Li LJ[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND/AIMS:[/h] Since the first case of novel H7N9 infection was reported, China has experienced five epidemics of H7N9. During the fifth wave, a highly pathogenic H7N9 strain emerged. In order to assess whether the H7N9 vaccine based on A/Zhejiang/DTID-ZJU01/2013(H7N9) was effective in protecting against highly pathogenic H7N9, we conducted this study.
[h=4]METHODS:[/h] Groups of mice were immunized twice by intraperitoneal injection with 500 ?l of either split vaccine alone or MF59-adjuvanted vaccine. Serum was collected 2 weeks after the second vaccine booster. The hemagglutinin inhibition test was conducted on vaccine seed and highly pathogenic H7N9 to evaluate the neutralization of highly pathogenic H7N9. We also immunized mice and challenged them with highly pathogenic H7N9. Mice were observed for illness, weight loss, and death at 1 week and 2 weeks post-infection. Then, the mice were sacrificed and lungs were removed. Antibody responses were assessed and pathological changes in the lung tissue were evaluated.
[h=4]RESULTS:[/h] The ability of serum to neutralize highly pathogenic H7N9 was reduced. In mice, highly pathogenic H7N9 was more virulent than A/Zhejiang/DTID-ZJU01/2013(H7N9). After challenge with highly pathogenic H7N9, all mice died while mice challenged with A/Zhejiang/DTID-ZJU01/2013(H7N9) all recovered. The A/ZJU01/PR8/2013 split H7N9 avian influenza vaccine was able to protect against infection with highly pathogenic H7N9 in mice, with or without MF59. Moreover, H7N9 vaccine adjuvanted with MF59 produced high antibody levels, which lead to better protection.
[h=4]CONCLUSIONS:[/h] The A/ZJU01/PR8/2013 split H7N9 avian influenza vaccine based on A/Zhejiang/DTID-ZJU01/2013(H7N9) is effective in protecting against highly pathogenic H7N9. H7N9 vaccine adjuvanted with MF59 offers better protection against infection with highly pathogenic H7N9. In order to make the H7N9 vaccine applicable to humans, further clinical trials are required to evaluate MF59 adjuvanted vaccine. Meanwhile, the vaccine strain should be updated based on the highly pathogenic H7N9 gene sequence.
? 2018 The Author(s). Published by S. Karger AG, Basel.
[h=4]KEYWORDS:[/h] Highly pathogenic H7N9; MF59 adjuvant; Protective immune responses; Split H7N9 vaccine
PMID: 29617693 DOI: 10.1159/000488631
Free full text